Trametinib upregulate tumour surface expression of MHC and PD-L1 in TNBC cells, resulting in increased TIL in a murine model of breast cancer. Combining MEK inhibition with PD-L1/PD-1 ICB demonstrated enhanced anti-tumour immune responses. This evidence concerns the gene PDCD1 and neoplasm.